Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01980706 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01980706 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 120 participants.
The verdict
NCT01980706, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The proposed study will carefully test the hypothesis that a robust dose of baclofen (90 mg/day) has efficacy and is safe in individuals with alcohol dependence. Furthermore, the proposal will test whether an indicator of physical dependence, i.e. drinks/drinking day, predicts response to baclofen. Additionally, the proposal will examine the anti-anxiety effects of baclofen within an alcohol dependent population and ascertain whether baseline levels of anxiety predict response to baclofen.
Interventions
- DRUG Placebo
- DRUG Baclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2013-12-12 |
| Est. Completion | 2017-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01980706
The ClinicalTrials.gov registry entry for NCT01980706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01980706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01980706 about?
NCT01980706 is a clinical study titled "Efficacy and Safety of High Dose Baclofen for Alcohol Dependence". The proposed study will carefully test the hypothesis that a robust dose of baclofen (90 mg/day) has efficacy and is safe in individuals with alcohol dependence. Furthermore, the proposal will test whether an indicator of physical dependence, i.e. drinks/drinking day, predicts response to baclofen. ...
What is the current status of trial NCT01980706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2013-12-12. Estimated completion is 2017-10-26.
What interventions are being tested in trial NCT01980706?
The interventions under investigation include: Placebo (DRUG), Baclofen (DRUG).
Who is sponsoring clinical trial NCT01980706?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.